In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

List today: Ares Management Corporation ARES is an alternative asset manager. The Zacks Consensus Estimate for its current ...

CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The ...

CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

Find all the latest Q3 results 2025 updates for TVS Srichakra, Rail Vikas Nigam, Shriram Properties, Ashok Leyland, Saint ...

Montreal West Day camp registration. The town announced that Montreal West residents should “get ready for an exciting summer at Day Camp! Camp will run from June 23 – Aug ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

CSL shares tumbled 4.95% on the day of its half-year results after revenue, net profits and dividends missed market ...

The reported net profit for the fourth quarter of 2024 stood at $399 million, a 21% beat compared to the Visible Alpha consensus of $329 million. The company's net debt was reported at $1,990 million, ...